{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T14:02:29Z","timestamp":1791295349135,"version":"4.1.0"},"reference-count":19,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2020,5,15]],"date-time":"2020-05-15T00:00:00Z","timestamp":1589500800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2020,5,15]],"date-time":"2020-05-15T00:00:00Z","timestamp":1589500800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/100005205","name":"Janssen Research and Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005205","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Acad Dermatol Venereol"],"published-print":{"date-parts":[[2020,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Patients treated with tumour necrosis factor (TNF) inhibitors are at risk of new\u2010onset tuberculosis (TB) or reactivation of latent tuberculosis infection (LTBI). Association between TB\/LTBI and interleukin (IL)\u201023 inhibitors for psoriasis is unclear. Patients with LTBI typically initiate LTBI therapy before receiving biologics.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Safety in moderate\u2010to\u2010severe psoriasis patients with LTBI treated with guselkumab (IL\u201023 inhibitor) and LTBI treatment was evaluated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In the VOYAGE 1 &amp; VOYAGE 2 studies, patients screened for LTBI were randomized to guselkumab, placebo, or adalimumab (TNF inhibitor) at baseline. Placebo\u00a0\u2192\u00a0guselkumab crossover occurred at week 16 and adalimumab\u00a0\u2192\u00a0guselkumab at week 52 (VOYAGE 1), or at week 28 or later (VOYAGE 2). Incidence of active TB, adverse events (AEs), serious AEs (SAEs), and markedly abnormal liver function tests [alanine aminotransferase test (ALT); aspartate aminotransferase test (AST)] were evaluated using pooled data through week 100 in guselkumab\u2010treated patients receiving and not receiving LTBI treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      At baseline, 130 randomized patients (guselkumab:\n                      <jats:italic>n<\/jats:italic>\n                      \u00a0=\u00a069; adalimumab:\n                      <jats:italic>n<\/jats:italic>\n                      \u00a0=\u00a036; placebo:\n                      <jats:italic>n<\/jats:italic>\n                      \u00a0=\u00a025) tested positive for LTBI and received concomitant LTBI treatments (LTBI+). No active TB was reported among guselkumab\u2010treated patients without LTBI (LTBI\u2212) through week 100. Two cases of active TB occurred in LTBI\u2212 patients treated with adalimumab. Through week 16, across all treatment groups, greater proportions of LTBI+ patients reported ALT and AST elevations compared with LTBI\u2212 patients. Through week 100, proportions of patients experiencing AEs and SAEs were comparable between LTBI+ and LTBI\u2212 patients.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>No cases of active TB, including reactivation of LTBI, were reported in patients with or without LTBI treated with guselkumab through up to 2\u00a0years. LTBI treatment was effective across all treatment groups in preventing reactivation of LTBI. Long\u2010term treatment with guselkumab was generally well\u2010tolerated through up to 2\u00a0years in patients receiving LTBI medications.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/jdv.16460","type":"journal-article","created":{"date-parts":[[2020,4,14]],"date-time":"2020-04-14T15:33:16Z","timestamp":1586878396000},"page":"1744-1749","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Safety in moderate\u2010to\u2010severe plaque psoriasis patients with latent tuberculosis treated with guselkumab and anti\u2010tuberculosis treatments concomitantly: results from pooled phase 3 VOYAGE 1 &amp; VOYAGE 2 trials"],"prefix":"10.1111","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6083-0952","authenticated-orcid":false,"given":"L.","family":"Puig","sequence":"first","affiliation":[{"name":"Hospital de la Santa Creu i Sant Pau Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.\u2010F.","family":"Tsai","sequence":"additional","affiliation":[{"name":"National Taiwan University Hospital Taipei Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Bhutani","sequence":"additional","affiliation":[{"name":"University of California San Francisco Medical Center San Francisco CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Uy","sequence":"additional","affiliation":[{"name":"Janssen Scientific Affairs, LLC Horsham PA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Ramachandran","sequence":"additional","affiliation":[{"name":"Janssen Research &amp; Development, LLC Spring House PA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Song","sequence":"additional","affiliation":[{"name":"Janssen Research &amp; Development, LLC Spring House PA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"You","sequence":"additional","affiliation":[{"name":"Janssen Research &amp; Development, LLC Spring House PA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Gooderham","sequence":"additional","affiliation":[{"name":"SKiN Centre for Dermatology Peterborough ON Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Lebwohl","sequence":"additional","affiliation":[{"name":"Icahn School of Medicine at Mount Sinai New York NY USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2020,5,15]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.06.056"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2016-012567"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.150057"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/1756-185X.12188"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01245-2015"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2008.03.023"},{"key":"e_1_2_6_8_1","volume-title":"Global Tuberculosis Report 2018","author":"World Health Organization","year":"2018"},{"key":"e_1_2_6_9_1","volume-title":"Latent Tuberculosis Infection: Updated and Consolidated Guidelines for Programmatic Management","author":"World Health Organization","year":"2018"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1746.2007.05207.x"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2012.11142.x"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/8909834"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/cti.2017.34"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2007.11.022"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.11.041"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.11.042"},{"key":"e_1_2_6_17_1","unstructured":"National Cancer Institute.Common Terminology Criteria for Adverse Events (CTCAE) v4.03 2010.https:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/ctc.htm"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.smim.2014.04.003"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1038\/cmi.2017.128"},{"key":"e_1_2_6_20_1","unstructured":"SKYRIZI\u2122 [package insert].AbbVie Inc. North Chicago IL 2019."}],"container-title":["Journal of the European Academy of Dermatology and Venereology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjdv.16460","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.16460","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jdv.16460","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.16460","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T13:40:12Z","timestamp":1791294012000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jdv.16460"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,15]]},"references-count":19,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["10.1111\/jdv.16460"],"URL":"https:\/\/doi.org\/10.1111\/jdv.16460","archive":["Portico"],"relation":{},"ISSN":["0926-9959","1468-3083"],"issn-type":[{"value":"0926-9959","type":"print"},{"value":"1468-3083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,15]]},"assertion":[{"value":"2019-12-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-03-27","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-05-15","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}